首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1624415

2024 年至 2031 年核酸分離和純化市場（按最終用戶、方法、核酸類型和地區劃分）

Nucleic Acid Isolation And Purification Market By End-User, Method, Nucleic Acid Type & Region for 2024-2031

出版日期: 2024年11月08日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年至 2031 年核酸分離與純化市場評估

隨著對精確分子診斷和標靶治療的需求不斷增長，對個人化醫療的不斷增長的需求預計將成為核酸分離和純化市場的主要驅動力。根據Verified Market Research分析師預測，2024年核酸分離與純化市值約48.8億美元，預測期間將達到87.8億美元的估值。

核酸分離和純化市場的快速擴張主要得益於生物技術和基因組學的不斷進步，預計這將大幅提高市場複合年增長率。預計這將有助於市場在 2024 年至 2031 年期間以 8.40% 的複合年增長率成長。

核酸分離與純化市場定義/概述

核酸分離與純化是分子生物學中的一個重要過程，旨在從生物樣本中提取和純化DNA、RNA和其他核酸。這些過程對於各種應用至關重要，包括基因研究、診斷和治療開發。有許多不同的技術用於分離和純化核酸，包括離心、過濾和基於磁珠的方法。這些步驟中獲得的核酸的品質和完整性對於後續的分析和應用至關重要。

生物技術和基因組學的不斷進步正在推動核酸分離和純化市場的顯著成長。個人化醫療的不斷增長的需求和高通量測序技術的進步預計將促進該市場的擴張。隨著研究和臨床應用的不斷發展，對高效、可靠的核酸分離和純化方法的需求預計將支持整體市場的成長。

推動核酸分離和純化市場成長的主要趨勢是什麼？

新一代定序 (NGS) 技術的日益普及極大地推動了核酸分離和純化市場的擴張。 NGS 技術為基因研究、個人化醫療和腫瘤學等各種應用提供了必需的高通量定序能力，徹底改變了基因組研究。根據 Verified Market Research 的數據，2024 年下一代定序 (NGS) 市場規模價值 88.7 億美元，預計到 2031 年將達到 391.5 億美元，2024-2031 年預測期內的複合年增長率為 20.39%。達到10萬美元。

對精確、準確的定序結果的需求推動了對高品質核酸樣本的需求，預計這將進一步推動核酸分離和純化產品市場的發展。因此，分離和純化技術的進步有望提高NGS的效率和有效性，從而促進市場成長。

影響核酸分離和純化市場的關鍵阻礙因素有哪些？

由於先進分離純化設備的成本較高，核酸分離純化市場面臨很大的阻礙因素。對於許多實驗室，特別是發展中地區的實驗室來說，複雜的技術和試劑所需的初始投資是難以承受的。

例如，自動化液體處理平台和高通量純化機等先進系統的成本可能超過 100,000 美元，從而限制了它們的可及性和採用。預計如此高的成本將抑制市場成長，尤其是在預算受限的地區。預計全球核酸分離和純化產品市場在資本取得有限的地區成長速度會較慢。因此，設備和試劑的高成本預計將成為市場擴張的重大障礙，影響整個產業的成長軌跡。

QIAGEN N.V.（Netherlands）
Thermo Fisher Scientific Inc.（US）
Roche Diagnostics（Switzerland）
Promega Corporation（US）
Agilent Technologies Inc.（US）
Merck KGaA, Darmstadt, Germany
Beckman Coulter Life Sciences（US）
GE Healthcare（US）
Bio-Rad Laboratories, Inc.（US）
Luminex Corporation（US）

第 11 章市場展望與機會

新興技術
未來市場趨勢
投資機會

第 12 章附錄

縮寫列表
來源與參考文獻

簡介目錄

Product Code: 24242

Nucleic Acid Isolation And Purification Market Valuation - 2024-2031

Increasing demand for personalized medicine is expected to be a key driver in the nucleic acid isolation and purification market, as the need for precise molecular diagnostics and targeted therapies continues to grow. According to the analyst from Verified Market Research, the Nucleic Acid Isolation And Purification Market is estimated to reach a valuation of USD 8.78 Billion over the forecast subjugating around USD 4.88 Billion valued in 2024.

The rapid expansion of the nucleic acid isolation and purification market is primarily driven by the growing advancements in biotechnology and genomics, which are anticipated to significantly boost the CAGR of the market. It enables the market to grow at aCAGR of 8.40% from 2024 to 2031.

Nucleic Acid Isolation And Purification Market: Definition/ Overview

Nucleic acid isolation and purification are critical processes in molecular biology, designed to extract and purify DNA, RNA, or other nucleic acids from biological samples. These processes are essential for a range of applications, including genetic research, diagnostics, and therapeutic development. Techniques employed in nucleic acid isolation and purification are varied and include methods such as centrifugation, filtration, and magnetic bead-based approaches. The quality and integrity of nucleic acids obtained through these processes are crucial for subsequent analysis and applications.

Increasing advancements in biotechnology and genomics are driving significant growth in the nucleic acid isolation and purification market. The rising demand for personalized medicine and advancements in high-throughput sequencing technologies are expected to contribute to this market's expansion. As research and clinical applications continue to evolve, the necessity for efficient and reliable nucleic acid isolation and purification methods is projected to increase, supporting the overall market growth.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Key Trends Driving Growth in the Nucleic Acid Isolation and Purification Market?

The expansion of the nucleic acid isolation and purification market is being significantly driven by the increasing adoption of next-generation sequencing (NGS) technologies. NGS technologies have revolutionized genomic research by providing high-throughput sequencing capabilities, which are essential for a variety of applications, including genetic research, personalized medicine, and oncology. According the Verified Market Research, the next-generation sequencing (NGS) market size was valued to be USD 8.87 Billion in the year 2024 and it is expected to reach USD 39.15 Billion in 2031, at a CAGR of 20.39% over the forecast period of 2024 to 2031.

The demand for high-quality nucleic acid samples is being propelled by the need for precise and accurate sequencing results, which is expected to further boost the market for nucleic acid isolation and purification products. Consequently, advancements in isolation and purification technologies are being anticipated to enhance the efficiency and effectiveness of NGS, leading to increased market growth.

What are the Key Restraints Affecting the Nucleic Acid Isolation and Purification Market?

The nucleic acid isolation and purification market faces significant constraints due to the high cost of advanced isolation and purification equipment. The initial investment required for sophisticated technologies and reagents can be prohibitive for many laboratories, particularly those in developing regions.

For instance, advanced systems such as automated liquid handling platforms and high-throughput purifiers can cost upwards of $100,000, which limits their accessibility and adoption. This high cost is projected to restrain market growth, particularly in regions where budget constraints are prevalent. It is estimated that the global market for nucleic acid isolation and purification products will experience slower growth rates in regions with less funding availability. Thus, the high cost of equipment and reagents is expected to be a significant barrier to market expansion, impacting the overall growth trajectory of the industry.

Category-Wise Acumens

Which is the Dominating End-User Segment in the Nucleic Acid Isolation and Purification Market?

According to VMR analyst, pharmaceutical and biotechnology companies are expected to dominate as the leading end-user segment. This dominance is attributed to the extensive use of nucleic acid isolation and purification techniques in drug discovery, development, and personalized medicine. It is anticipated that these companies will continue to drive demand due to their need for high-quality nucleic acid samples for genetic research, biomarker discovery, and therapeutic development.

The pharmaceutical and biotechnology sector is projected to account for the largest share of the market, driven by the increasing number of drug development projects and rising investments in biotechnology research.

Which Nucleic Acid Type is Expected to Experience Rapid Growth in the Nucleic Acid Isolation and Purification Market?

In the nucleic acid isolation and purification market, RNA isolation is projected to experience rapid growth compared to other nucleic acid types. This growth is largely driven by the rising prevalence of RNA-based therapies and the increasing use of RNA in molecular diagnostics and research.

The growing interest in RNA sequencing and the development of RNA-targeted treatments are anticipated to fuel demand for RNA isolation products. The RNA isolation segment is expected to witness a significant increase in market share, driven by advancements in RNA extraction technologies and the expanding applications of RNA in personalized medicine.

Country/Region-wise Acumens

What are the Key Factors Driving the Growth of the Nucleic Acid Isolation and Purification Market in North America?

According to VMR Analyst, in North America, the nucleic acid isolation and purification market is expected to experience substantial growth, driven by several key factors. The region's advanced healthcare infrastructure, significant investments in research and development, and high concentration of leading pharmaceutical and biotechnology companies are anticipated to contribute to its dominance.

The U.S. government allocated over USD 3.8 Billion to the

Human Genome Project

between 1990 and 2003, with funding provided by the National Institutes of Health (NIH) and the Department of Energy (DOE). Additionally, the NIH's "All of Us" Research Program has been granted USD 1.5 Billion over ten years starting from 2016. This initiative aims to enhance precision medicine by gathering comprehensive health data from a diverse population to better understand the impact of individual differences on health and treatment.

Additionally, the strong presence of academic research institutes and diagnostic centers in North America is likely to further support market expansion. The increasing adoption of next-generation sequencing (NGS) technologies and rising demand for personalized medicine are projected to drive the need for efficient nucleic acid isolation and purification solutions.

How is the Nucleic Acid Isolation and Purification Market Expected to Evolve in Asia Pacific?

In Asia Pacific, the nucleic acid isolation and purification market is projected to grow rapidly due to increasing investments in healthcare infrastructure and expanding research activities. The region's growing emphasis on biotechnology and genomics research, coupled with rising government funding for scientific research, is anticipated to drive market growth.

The increasing prevalence of chronic diseases and the expansion of diagnostic services are also expected to contribute to the demand for nucleic acid isolation and purification products. Moreover, the rise of local pharmaceutical and biotechnology companies and contract research organizations (CROs) is likely to further accelerate market expansion.

In 2020, Asia accounted for approximately 49.3% of global cancer cases, with around 9.5 million new diagnoses reported. However, the region's share of cancer-related deaths was notably higher, representing about 58.3% of the global total, translating to approximately 5.8 million fatalities. These statistics highlight Asia's significant burden of cancer, reflecting both the high incidence and mortality rates within the region.

Competitive Landscape

The Nucleic Acid Isolation And Purification Market's competitive landscape is characterized by a varied range of companies, including technology developers, plant operators, and service providers, all striving for market share in an increasingly dynamic and growing industry.

Some of the prominent players operating in the nucleic acid isolation and purification market include:

Agilent Technologies, Inc.

Beckman Coulter Life Sciences

Bio-Rad Laboratories, Inc.

GE Healthcare

Luminex Corporation

Merck KGaA

Promega Corporation

QIAGEN N.V.

Roche Diagnostics

Thermo Fisher Scientific, Inc.

Latest Developments

In December 2023, Thermo Fisher Scientific Inc. introduced two new products: the Thermo Scientific KingFisher Apex Dx, an automated nucleic acid purification instrument, and the Applied Biosystems MagMAX Dx Pathogen/Viral NA Isolation Kit. These innovations are designed to enhance the isolation and purification of bacterial and viral pathogens from biological samples.

In November 2023, LGC Biosearch Technologies announced the acquisition of PolyDesign, a company specializing in solid support embedded frits used for DNA and RNA oligonucleotide synthesis and purification. This technology complements LGC's Nucleic Acid Chemistry product range.

In August 2023, CD Bioparticles introduced a new series of DNA Extraction and Purification Kits. These kits are designed for efficient and rapid isolation of various DNA types, including plasmid, genomic, cell-free (cfDNA), mitochondrial, tissue DNA, and PCR products.

In July 2023, INOVIQ Limited and Promega Corporation revealed a global marketing collaboration to promote Promega's Nucleic Acid purification systems and EXO-NET exosome capture technology.

In February 2023, Agilent Technologies, Inc. selected Fluor Corporation's Advanced Technologies & Life Sciences division to expand its oligonucleotide therapeutics manufacturing facility in Colorado, enhancing capabilities for synthesizing, lyophilizing, and purifying custom nucleic acid therapeutics.

In January 2023, QIAGEN launched the EZ2 Connect MDx platform, an automated solution for diagnostic labs that streamlines the purification of DNA and RNA from up to 24 samples in under 30 minutes.